Hedgehog Drug Helps Late-Stage Cancers

Links shared publicly online about this topic.

  • 1,777
    total visits

Hedgehog Drug Helps Late-Stage Cancers

webmd.com

People with advanced skin and brain cancers -- untreatable by current methods -- improve after treatment with a new oral drug called a hedgehog inhibitor.

View full resource at webmd.com

Tags: Skin, Brain, Cancer, Brain Cancer, Drug

  • Share

Most Recently Shared on September 4, 2009 at 5:20 pm By:

WebMD_Cancer WebMD Cancer

Experimental 'Hedgehog' Drug Targets Cancer http://bit.ly/BFYCK

3 years ago...

Also Shared By:

Heart Health Heart Health

WebMD_News WebMD_News

New drug helping men with prostate cancer

wndu.com — “A drug being investigated right now could prove to be a big breakthrough for men with late stage prostate cancer, especially in cases where the disease has spread to the bone.View full resource at wndu.com

  • View Related
  • Share

Most Recently Shared on April 26, 2012 at 8:41 pm By:

BoneCancer_OW Bone Cancer OW OW Health

Controversial drug helping men with prostate cancer: A drug being investigated right now could prove to be a big... http://t.co/nx4NHjBJ

3 weeks ago...

Prostate Cancer Drug Improves Survival | ThirdAge

thirdage.com — “A prostate cancer experimental drug from Medivation Inc. helped patients live longer in a late-stage clinical trial, the biotechnology company said Thursday.View full resource at thirdage.com

  • View Related
  • Share

Most Recently Shared on November 5, 2011 at 1:58 pm By:

FDA Approves Xalkori With Companion Diagnostic For A Type Of Late-stage Lung Cancer - QualityPoint Technologies

qualitypointtech.net — “The U.S. Food and Drug Administration approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene. Xalkori is being approved with a companion diagnostic test that will help determine if a patient has the abnormal ALK gene, a first-of-a-kind genetic test called the Vysis ALK Break Apart FISH Probe Kit. It is the second such targeted therapy approved by tView full resource at qualitypointtech.net

  • View Related
  • Share

Most Recently Shared on August 27, 2011 at 12:00 pm By:

MedicalFeed MedicalFeed Health News Feed

FDA Approves Xalkori With Companion Diagnostic For A Type Of Late-stage Lung Cancer: The U.S. Food and Drug Admini... http://t.co/6HRx8I6

9 months ago...

FDA Approves Xalkori With Companion Diagnostic For A Type Of Late-stage Lung Cancer - QualityPoint Technologies

qualitypointtech.net — “The U.S. Food and Drug Administration approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene. Xalkori is being approved with a companion diagnostic test that will help determine if a patient has the abnormal ALK gene, a first-of-a-kind genetic test called the Vysis ALK Break Apart FISH Probe Kit. It is the second such targeted therapy approved by tView full resource at qualitypointtech.net

  • View Related
  • Share

Most Recently Shared on August 27, 2011 at 9:45 am By:

MedicalFeed MedicalFeed Health News Feed

FDA Approves Xalkori With Companion Diagnostic For A Type Of Late-stage Lung Cancer: The U.S. Food and Drug Admini... http://t.co/Dab3lox

9 months ago...

Late-Stage Ovarian Cancer Therapy Shows Promise in Phase II Trial

newswise.com — “An experimental two-drug combination for treating late-stage ovarian cancer continues to produce strong results. Its Indiana U. researchers say they may have discovered biomarkers that could help identify women who would respond best to the therapy.View full resource at newswise.com

  • View Related
  • Share

Most Recently Shared on August 2, 2011 at 9:28 pm By:

OvarianCancer_ Ovarian Cancer OW OW Health

Late-Stage Ovarian Cancer Therapy Shows Promise in Phase II Trial: An experimental two-drug combination for trea... http://bit.ly/p8pbAx

9 months ago...

Late-Stage Ovarian Cancer Therapy Shows Promise in Phase II Trial

newswise.com — “An experimental two-drug combination for treating late-stage ovarian cancer continues to produce strong results. Its Indiana U. researchers say they may have discovered biomarkers that could help identify women who would respond best to the therapy.View full resource at newswise.com

  • View Related
  • Share

Most Recently Shared on August 2, 2011 at 4:49 pm By:

mednewswise Thom Canalichio Health News

Late-Stage Ovarian Cancer Therapy Shows Promise in Phase II Trial: An experimental two-drug combination ... http://bit.ly/qAuA96 #cancer

9 months ago...

Novartis Gets Good News on Cancer Drug Afinitor - FoxNews.com

foxnews.com — “Novartis AG said a late-stage study showed its drug hope Afinitor slowed tumor growth in advanced breast cancer, helping its chances of becoming a new blockbuster treatmentView full resource at foxnews.com

  • View Related
  • Share

Most Recently Shared on July 7, 2011 at 12:48 am By:

Novartis gets good news on cancer drug Afinitor | Reuters

reuters.com — “ZURICH (Reuters) - Novartis AG said a late-stage study showed its drug hope Afinitor slowed tumor growth in advanced breast cancer, helping its chances of becoming a new blockbuster treatment.The SwissView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on July 6, 2011 at 2:37 am By:

hrana Hisham Rana, MD Doctor and Physician

News: Novartis gets good news on cancer drug Afinitor http://reut.rs/qk1Cl4 - #health #pharma

10 months ago...

Novartis gets good news on cancer drug Afinitor | Reuters

reuters.com — “ZURICH (Reuters) - Novartis AG said a late-stage study showed its drug hope Afinitor slowed tumor growth in advanced breast cancer, helping its chances of becoming a new blockbuster treatment.The SwissView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on July 5, 2011 at 10:20 pm By:

Novartis gets good news on cancer drug Afinitor | Reuters

reuters.com — “ZURICH (Reuters) - Novartis AG said a late-stage study showed its drug hope Afinitor slowed tumor growth in advanced breast cancer, helping its chances of becoming a new blockbuster treatment.The SwissView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on July 5, 2011 at 10:08 pm By:

Reuters_Health Reuters Health Health News

Novartis gets good news on cancer drug Afinitor http://reut.rs/q4Eu6I

10 months ago...

Novartis gets good news on cancer drug Afinitor | Reuters

reuters.com — “ZURICH (Reuters) - Novartis AG said a late-stage study showed its drug hope Afinitor slowed tumor growth in advanced breast cancer, helping its chances of becoming a new blockbuster treatment.The SwissView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on July 5, 2011 at 9:51 pm By:

MedicalNews Medical News Health News

Novartis gets good news on cancer drug Afinitor http://bit.ly/omnKML

10 months ago...

Chemo for Late-Stage Cancer Patients May Be Unjustified - Drugs.com MedNews

drugs.com — “Some patients with advanced cancer receive drugs that won t help them but could cause them harm, a U.S. study suggests. University of Chicago researchers analyzView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on June 9, 2011 at 10:55 pm By:

drugscom Drugs.com Health Site

Chemo for Late-Stage Cancer Patients May Be Unjustified - http://bit.ly/kDOv7J

11 months ago...

Roche's Tarceva helps lung cancer patients | Reuters

reuters.com — “ZURICH (Reuters) - Roche Holding AG's cancer drug Tarceva nearly doubles the time patients with a distinct type of lung cancer live without their disease getting worse, a late-stage trial showed on Friday.TheView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on June 4, 2011 at 5:38 am By:

LungCancer Lung Cancer OW OW Health

Roche's Tarceva helps lung cancer patients: ZURICH (Reuters) - Roche Holding AG's cancer drug Tarceva nearly dou... http://bit.ly/mzeU6t

11 months ago...

Roche's Tarceva helps lung cancer patients | Reuters

reuters.com — “ZURICH (Reuters) - Roche Holding AG's cancer drug Tarceva nearly doubles the time patients with a distinct type of lung cancer live without their disease getting worse, a late-stage trial showed on Friday.TheView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on June 3, 2011 at 5:12 pm By:

Roche's Tarceva helps lung cancer patients | Reuters

reuters.com — “ZURICH (Reuters) - Roche Holding AG's cancer drug Tarceva nearly doubles the time patients with a distinct type of lung cancer live without their disease getting worse, a late-stage trial showed on Friday.TheView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on June 3, 2011 at 4:46 pm By:

Advertisement